Evox Therapeutics

Per Lundin, Ph.D., CEO and Co-Founder

Oxford, UK

(Private)

Evox Therapeutics is a privately owned biotechnology company headquartered in Oxford, UK. We specialize in developing exosome-based therapeutics for severe, life-threatening rare diseases. Our proprietary ExoEdit™ platform allows us to engineer exosomes—natural extracellular vesicles—to deliver genome editing tools to targeted cells and tissues, addressing challenges associated with traditional therapies. We are advancing a pipeline aimed at treating CNS conditions such as amyotrophic lateral sclerosis and spinocerebellar ataxia type 2. We have a track record of impactful partnerships, including with Eli Lilly and Takeda, to develop exosome-based therapies for neurological disorders, showcasing the therapeutic potential of our platform. Over the years, we have attracted substantial investment, including a $95 million Series C funding round in 2021, to support the development of our innovative therapies.

www.evoxtherapeutics.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions